$TFX

Teleflex (NYSE:TFX) said non product-related disruption during BIOTRONIK Vascular Intervention integration affected the acquired revenue base. It now expects full integration through 2H26. Teleflex completed its OEM sale, raising about $1.5B proceeds, and repurchased 1.9M shares for $250M. 2026 pro forma revenue growth guidance was cut to 3.5% to 4.5%, while adjusted EPS was raised to $6.90 to $7.20.

Teleflex (NYSE:TFX) reported Q2 CY2026 results. Revenue rose 28.9% year on year to $570.3 million, topping Wall Street estimates by 2%, according to the company. Non-GAAP adjusted EPS was $1.76, 37.4% above analysts’ consensus. The article also cites full-year EPS expectations of $8.86 versus $8.75.

TELEFLEX INC (TFX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991to8-6x2026req2earning.htm EX-99.1 Document Exhibit 99.1 FOR IMMEDIATE RELEASE August 6, 2026 Teleflex Reports Second Quarter Finan cial Results and Full Year 2026 Outlook Completes Sale of OEM Business and Will Deploy Net Proceeds to Reduce Debt and Repurchase Comm

Teleflex (NYSE: TFX) is set to report Q2 earnings Thursday. The article notes last quarter’s revenue of $548.3 million, up 32.3% year on year, with EPS beating but full-year EPS guidance missing. Consensus expects Q2 revenue up 26.4% year on year. Analysts’ estimates were largely unchanged; the average price target is $149.45 versus $141.68.

TELEFLEX INC (TFX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. tfx-20260803 0000096943 false 0000096943 2026-08-03 2026-08-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported) Aug

Teleflex (TFX) said the U.S. FDA approved its Biologics License Application for EZPLAZ Freeze Dried Plasma for adult transfusion in bleeding-related conditions when plasma is needed and other plasma products are unavailable. The product is shelf-stable in a flexible plastic bag. Teleflex noted it is its first biologics license for a blood component and cited DHA WPAC support. TFX stock closed at $134.65.

TELEFLEX INC (TFX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 2 d138783dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 Execution Version TELEFLEX INCORPORATED AND EACH OF THE GUARANTORS PARTY HERETO 5.875% SENIOR NOTES DUE 2032 INDENTURE Dated as of June 15, 2026 U.S. Bank Trust Company, National Association Trustee TABLE OF CONTENTS Page ARTICL

TELEFLEX INC (TFX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. tfx-20260608 0000096943 false 0000096943 2026-06-08 2026-06-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported) Jun

The article compares medical device firms Teleflex (NYSE:TFX) and Advanced Biomedical Technologies (OTCMKTS:ABMT) across ownership, earnings, risk, profitability, dividends, valuation, and analyst views. Teleflex has a consensus $144 price target (11.79% upside) and lower beta (0.82 vs. 1.51). It also cites 95.6% institutional ownership for Teleflex.

Teleflex Incorporated announced new clinical data for its UroLift System and Barrigel rectal spacer at recent medical conferences. The UroLift study showed a significantly lower rate of catheterization compared to a competitor, while the Barrigel study indicated zero percent Grade 2+ toxicity at three years. Despite a planned divestiture of its Interventional Urology unit, Teleflex is expected to maintain profitability and stock value.